Last reviewed · How we verify
Moderate to severe atopic dermatitis in adults
Approved treatments
- Abrocitinib Suspension F1 · Pfizer
- Abrocitinib Suspension F6 · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe atopic dermatitis in adults patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe atopic dermatitis in adults treatment landscape brief
- Moderate to severe atopic dermatitis in adults treatment updates RSS
Frequently asked questions about Moderate to severe atopic dermatitis in adults
What drugs treat Moderate to severe atopic dermatitis in adults?
Tracked treatments include Abrocitinib Suspension F1, Abrocitinib Suspension F6.
What is the treatment for Moderate to severe atopic dermatitis in adults?
Standard treatment for Moderate to severe atopic dermatitis in adults includes Abrocitinib Suspension F1, Abrocitinib Suspension F6. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe atopic dermatitis in adults patent cliff · Moderate to severe atopic dermatitis in adults CI report
- Treatment: Abrocitinib Suspension F1 · Pfizer
- Treatment: Abrocitinib Suspension F6 · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing